ENTA

Enanta Pharmaceuticals, Inc. Press Releases

$29.19
*  
0.58
1.95%
Get ENTA Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading ENTA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2016
4/27/2016 4:05:00 PM - Business Wire
▼-8.24 % Price Change since this news event. The Volume Ratio is 3.31.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Enanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4, 2016 at 8:00 A.M. ET
4/26/2016 8:00:00 AM - Business Wire
▼-8.52 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Enanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
4/25/2016 9:10:00 AM - Business Wire
▼-8.15 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Enanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
4/16/2016 1:10:00 AM - Business Wire
▼-7.30 % Price Change since this news event. The Volume Ratio is 2.39.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
4/15/2016 1:15:00 AM - Business Wire
▼-7.69 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients
4/14/2016 1:11:00 AM - Business Wire
▼-7.63 % Price Change since this news event. The Volume Ratio is 0.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress™ 2016
3/30/2016 7:07:00 AM - Business Wire
▲4.59 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference
3/10/2016 8:00:00 AM - Business Wire
▲2.21 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Enanta Pharmaceuticals Announces CHMP Positive Opinion for AbbVie’s VIEKIRAX® + EXVIERA® Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis
2/26/2016 9:52:00 AM - Business Wire
▲1.21 % Price Change since this news event. The Volume Ratio is 2.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
2/8/2016 4:02:00 PM - Business Wire
▲35.64 % Price Change since this news event. The Volume Ratio is 4.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day